Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

January 30, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

The global human growth hormone market size was valued at USD 6.81 billion in 2024 and is projected to reach from USD 7.63 billion in 2025 to USD 18.75 billion by 2033, growing at a CAGR of 11.90% ...

In a report released today, Chris Schott from J.P. Morgan maintained a Hold rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

CGRP Inhibitors Market. The global CGRP inhibitors market is poised for robust growth, with its valuation expected to rise ...

BioAge stated that it was collaborating with Eli Lilly and Company (“Lilly”) in connection with ... as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its ...

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

A price cut for semaglutide in Medicare could also have spillover effects, pressuring prices for Eli Lilly’s Mounjaro ...